Our hypothetical power analysis estimates that a trial targeted to neuropathic GBA‐PD could shrink the sample size required by as much as 25‐fold compared to an equally powered trial of PD patients without a GBA mutation (Fig 3). Here, GBA1 is linked to Parkinson disease.